Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series (Q35021812)

5 August 2017

Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series (English)

1 reference

5 August 2017

1 reference

1 reference

Ritu Valiyil

1

1 reference

5 August 2017

Livia Casciola-Rosen

2

1 reference

5 August 2017

Grace Hong

3

1 reference

5 August 2017

Andrew Mammen

4

1 reference

5 August 2017

Lisa Christopher-Stine

5

1 reference

5 August 2017

1 September 2010

1 reference

Arthritis Care and Research

5 August 2017

1 reference

5 August 2017

62

1 reference

5 August 2017

9

1 reference

5 August 2017

1328-1334

1 reference

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Myopathy with antibodies to the signal recognition particle: clinical and pathological features

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Autoantibody profiles in the sera of European patients with myositis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Polymyositis and dermatomyositis (first of two parts)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion.

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FACR.20219

Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107255

Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)

25 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FACR.20219

The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen

21 January 2018

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

Efficacy of rituximab in refractory polymyositis

1 reference

12 December 2020

Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology

1 reference

12 December 2020

Identifiers

DOI

10.1002/ACR.20219

1 reference

5 August 2017

1 reference

5 August 2017

1 reference